Intas Pharmaceuticals Limited — Ondansetron Exporter Profile
Indian Pharmaceutical Exporter · #12 for Ondansetron · $2.5M export value · DGFT Verified
Intas Pharmaceuticals Limited is the #12 Indian exporter of Ondansetron with $2.5M in export value and 511 verified shipments. Intas Pharmaceuticals Limited holds a 2.1% market share in Ondansetron exports across 15 countries. The company exports 75 pharmaceutical products worth $372.3M across 19 therapeutic categories.
Intas Pharmaceuticals Limited — Ondansetron Export Profile: Buyers & Destinations
Where Does Intas Pharmaceuticals Limited Export Ondansetron?
| Country | Value | Shipments | Share |
|---|---|---|---|
| MEXICO | $593.7K | 68 | 24.6% |
| UNITED STATES | $429.5K | 15 | 17.8% |
| NETHERLANDS | $314.2K | 75 | 13.0% |
| ITALY | $181.2K | 110 | 7.5% |
| POLAND | $160.7K | 32 | 6.7% |
| SPAIN | $153.8K | 15 | 6.4% |
| UNITED KINGDOM | $138.6K | 19 | 5.7% |
| AUSTRALIA | $127.3K | 11 | 5.3% |
| SINGAPORE | $106.6K | 7 | 4.4% |
| FRANCE | $96.7K | 7 | 4.0% |
Intas Pharmaceuticals Limited exports Ondansetron to 15 countries. The largest destination is MEXICO accounting for 24.6% of Intas Pharmaceuticals Limited's Ondansetron shipments, followed by UNITED STATES (17.8%) and NETHERLANDS (13.0%). These destinations reflect Intas Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Ondansetron from Intas Pharmaceuticals Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| EVERSANA LIFE SCIENCES SERVICES,LLC | UNITED STATES | $417.3K | 14 |
| TO THE ORDER | UNITED KINGDOM | $231.0K | 54 |
| ACCORD FARMA S.A. DE C.V. | MEXICO | $172.3K | 18 |
| ACCORD FARMA S.A.DE C.V | MEXICO | $144.8K | 22 |
| ACCORD UK | UNITED KINGDOM | $132.1K | 14 |
| ACCORD FARMA S A DE C V | MEXICO | $131.1K | 5 |
| ACCORD HEALTHCARE PTE LTD | SINGAPORE | $106.6K | 7 |
| ALLOGA FRANCE | FRANCE | $96.7K | 7 |
| ACCORD HEALTHCARE POLSKA SP. Z O.O. | POLAND | $88.5K | 11 |
| ACCORD HEALTHCARE ITALIA SRL | ITALY | $82.8K | 10 |
Intas Pharmaceuticals Limited supplies Ondansetron to 51 buyers globally. The largest buyer is EVERSANA LIFE SCIENCES SERVICES,LLC (UNITED STATES), followed by TO THE ORDER (UNITED KINGDOM) and ACCORD FARMA S.A. DE C.V. (MEXICO). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Ondansetron Export Value and How Much Does Intas Pharmaceuticals Limited Contribute?
India exported $100.2M worth of Ondansetron through 8,469 shipments from 537 suppliers to 157 countries, serving 1,636 buyers globally. Intas Pharmaceuticals Limited contributes $2.5M to this total, accounting for 2.1% of India's Ondansetron exports. Intas Pharmaceuticals Limited ships Ondansetron to 15 countries through 51 buyers.
What Is the Average Shipment Value for Intas Pharmaceuticals Limited's Ondansetron Exports?
Intas Pharmaceuticals Limited's average Ondansetron shipment value is $4.9K per consignment, based on 511 shipments totaling $2.5M. The largest destination is MEXICO (24.6% of Intas Pharmaceuticals Limited's Ondansetron exports).
How Does Intas Pharmaceuticals Limited Compare to Other Indian Ondansetron Exporters?
Intas Pharmaceuticals Limited ranks #12 among 537 Indian Ondansetron exporters with a 2.1% market share. The top 3 exporters are AUROBINDO PHARMA LTD ($31.2M), GLENMARK PHARMACEUTICALS LIMITED ($15.9M), BAXTER PHARMACEUTICALS INDIA PRIVATE LIMITED ($10.8M). Intas Pharmaceuticals Limited processed 511 shipments to 15 destination countries.
What Ondansetron Formulations Does Intas Pharmaceuticals Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHARMA DRUGS & MEDI ONDANSETRON INJ USP | $256.7K | 9 |
| PHARMA DRUGS & MEDI ONDANSETRON BLS,2MG/ | $129.6K | 22 |
| PH.DRU.& MED. HT-BLOC 8MG/4ML INJ. - 3 AMPOULES EACH ML CONTAINS: ONDANSETRON HYDROCHLORIDE DIHYDRATE PH.EUR EQ.TO | $122.1K | 6 |
| PHR DRUGS & MEDI ONDANSETRON INJ USP 2MG | $84.2K | 3 |
| PHR DRUGS&MEDI ONDANSETRON INJ USP 2MG/M | $76.4K | 2 |
| PHARMA DRUGS & MEDI ONDANSETRON ACCORD 4MG/2ML 2X5A AUS AS PER INVOICEVLS | $64.7K | 5 |
| PHARMA DRUGS & MEDI ONDANSETRON BLS2MG/M | $58.6K | 4 |
| PHARMA.DRUGS & MEDICINE HT-BLOC 4MG/2MLINJ-1 AMPOULES EACH ML CONT.ONDANSETRONHYDROCHLORIDE DIHYDRATE PH.EUR EQ.TO ONDVLS | $58.6K | 3 |
| PHARMA DRUGS AND MEDI HT-BLOC 8MG/4ML INJ. - 3 AMPOULES EACH ML CONTAINS: ONDANSETRON HYDROCHLORIDE DIHYDRATE PH.EUR EQ. | $58.3K | 3 |
| PHARMA DRUGS AND MEDI HT-BLOC 8MG/4ML INJ.-3 AMPOULES EACH ML CONTAINS: ONDANSETRON 2MG WATER FOR INJECTION PH.EUR | $50.0K | 1 |
Intas Pharmaceuticals Limited exports 279 distinct Ondansetron formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHARMA DRUGS & MEDI ONDANSETRON INJ USP with 9 shipments worth $256.7K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Ondansetron to Key Markets
What Intas Pharmaceuticals Limited must comply with to export Ondansetron to its top destination countries
Mexico — COFEPRIS
Approval Process
Generic registration under Mexican health law. NOM standards apply.
Timeline: 12–18 months
GMP & Export Requirements
Mexican GMP (NOM-059-SSA1); COFEPRIS overseas inspection or PIC/S certificate
Sanitary Import Permit from COFEPRIS; import licence via SAT
Note: COFEPRIS participates in PIC/S, easing recognition of PIC/S certificates from Indian authorities.
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Intas Pharmaceuticals Limited Compare to Nearest Ondansetron Exporters?
Exporters ranked immediately above and below #12 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 10 | CIPLA LIMITED | $3.0M | 204 | 7 | $14.5K |
| 11 | IPCA LABORATORIES LIMITED | $2.8M | 80 | 3 | $35.4K |
| 12 | INTAS PHARMACEUTICALS LIMITED ★ | $2.5M | 511 | 15 | $4.9K |
| 13 | DR REDDYS LABORATORIES LIMITED | $1.9M | 58 | 3 | $33.4K |
| 14 | NATCO PHARMA LIMITED | $1.6M | 90 | 3 | $18.0K |
Intas Pharmaceuticals Limited ranks #12 among 537 Indian Ondansetron exporters. Average shipment value of $4.9K compared to the market average of $186.5K. The closest competitors by value are CIPLA LIMITED and IPCA LABORATORIES LIMITED.
Which Indian Ports Ship Ondansetron Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 1,058 | 12.5% |
| NHAVA SHEVA SEA (INNSA1) | 1,026 | 12.1% |
| SAHAR AIR | 993 | 11.7% |
| HYDERABAD ICD (INSNF6) | 509 | 6.0% |
| HYDERABAD ICD | 448 | 5.3% |
| JNPT/ NHAVA SHEVA SEA | 343 | 4.1% |
| DELHI AIR CARGO ACC (INDEL4) | 265 | 3.1% |
| AHEMDABAD AIR ACC (INAMD4) | 224 | 2.6% |
Geopolitical & Trade Policy Impact on Intas Pharmaceuticals Limited's Ondansetron Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Intas Pharmaceuticals. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and raised freight rates by 40–50% on key India–Europe routes, impacting the cost-effectiveness and timeliness of exports. (livemint.com)
Conversely, the ongoing US-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the U.S. market. Intas's acquisition of UDENYCA® and the FDA's acceptance of its biosimilar applications position the company to leverage these opportunities effectively. However, compliance with the European Union's Falsified Medicines Directive (FMD) remains a critical factor for market access. Intas's proactive approach in securing partnerships and ensuring regulatory compliance underscores its commitment to maintaining and expanding its presence in the European market.
Intas Pharmaceuticals Limited — Regulatory Compliance & Quality Standards
Maintaining stringent regulatory compliance is paramount for Indian pharmaceutical exporters. Intas Pharmaceuticals has demonstrated a strong commitment to adhering to international quality standards, as evidenced by its successful acquisitions and partnerships that necessitate compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP). The company's proactive engagement in regulatory processes, such as the FDA's acceptance of its Biologics License Application for DMB-3115, reflects its dedication to quality and compliance. (intaspharma.com) As global regulatory requirements continue to evolve, Intas's focus on quality assurance and compliance positions it favorably in the competitive pharmaceutical export market.
About Intas Pharmaceuticals Limited
Intas Pharmaceuticals Limited exports 75 products worth $372.3M. Beyond Ondansetron, top products include Ras, Mycophenolate, Tacrolimus, Apixaban, Ezetimibe. View the complete Intas Pharmaceuticals Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Ondansetron — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Ondansetron shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Intas Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 517 individual customs records matching Intas Pharmaceuticals Limited exporting Ondansetron, covering 279 formulations to 15 countries via 51 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 157+ countries, 1,636+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Ondansetron Export Data from Intas Pharmaceuticals Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Intas Pharmaceuticals Limited's Ondansetron exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Intas Pharmaceuticals Limited
Full Company Profile →
75 products · $372.3M total trade · 19 categories
Ondansetron Stats
Company Overview
Top Products by Intas Pharmaceuticals Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Intas Pharmaceuticals Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Ondansetron. For current shipment-level data, contact TransData Nexus.